Myriad Genetics Inc expected to post a loss of 6 cents a share - Earnings Preview

Myriad Genetics

28/07/2026 21:46

Myriad Genetics Inc MYGN.OQ MYGN.O is expected to  show a fall in quarterly revenue when it reports  results on July 30 for the period ending June 30 2026
The Salt Lake City Utah-based  company is expected to report a 3.3% decrease in revenue to $206.029 million from $213.1 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.The company's guidance on May 5 2026, for the period ended June 30, was for revenue between $202.40 million and $206.41 million. (Sales Majority is on Total / Net Revenue basis)
​LSEG's mean analyst estimate for Myriad Genetics Inc is for a loss of 6 cents per share. 
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and 2 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Myriad Genetics Inc is $6.00, about 10.1% above its last closing price of $5.45
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.07
-0.07
-0.09
Missed
-31.5
Dec. 31 2026
-0.02
-0.01
0.04
Beat
373.6
Sep. 30 2025
-0.01
-0.01
0.00
Beat
100​
Jun. 30 2025
-0.01
-0.01
0.05
Beat
638.2
​​Mar. 31 2025
-0.06
-0.06
-0.03
Beat
48.9
Dec. 31 2024
0.03
0.03
0.03
Met
-1​
Sep. 30 2024
0.02
0.02
0.06
Beat
211.4
Jun. 30 2024
-0.01
-0.01
0.05
Beat
508.8
This summary was machine generated July 28 at 20:46 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)